Financial Performance - For the first quarter of 2021, the company reported revenue of RMB 80,894,000, a significant increase of 72% compared to RMB 47,089,000 in the same period of 2020[14] - The gross profit for the first quarter of 2021 was RMB 35,304,000, compared to RMB 14,311,000 in the first quarter of 2020, reflecting a gross margin improvement[14] - The net profit for the first quarter of 2021 was RMB 405,000, a recovery from a net loss of RMB 17,464,000 in the same quarter of the previous year[14] - The company’s operating loss decreased to RMB 1,842,000 in the first quarter of 2021 from a loss of RMB 2,723,000 in the same quarter of 2020[14] - The total comprehensive income for the first quarter of 2021 was RMB 421,000, compared to a loss of RMB 17,531,000 in the same period of 2020[16] - The company reported a basic and diluted loss per share of RMB 0.01 for the first quarter of 2021, an improvement from a loss of RMB 0.11 per share in the same quarter of 2020[14] - The loss attributable to shareholders for the three months ended March 31, 2021, was RMB 0.65 million, a 96% reduction from a loss of RMB 15.80 million in the same period last year[36] - The total comprehensive income for the three months ended March 31, 2021, was a loss of RMB 15.86 million, reflecting the impact of operational challenges[31] Research and Development - The company incurred research and development expenses of RMB 5,800,000 in the first quarter of 2021, compared to RMB 5,279,000 in the same period of 2020[14] - The company is committed to ongoing research and development to innovate and improve its product line[19] - The company is focusing on the development of in vitro diagnostic products and services, aiming to enhance its competitive edge through independent research and development[40] - The company aims to enhance its product quality and continuously develop new testing projects in response to industry technological advancements[40] Market Presence and Strategy - The company aims to continue expanding its market presence and enhancing its product offerings in the in vitro diagnostic sector[19] - The domestic in vitro diagnostic reagent market still sees over 50% demand from biochemical and immunodiagnostic reagents, indicating a significant market share[38] - The company anticipates that the domestic health industry will continue to grow due to factors such as an aging population and increased health awareness[37] Corporate Governance - The company has complied with all provisions of the Corporate Governance Code, except for specific provisions A.1.8 and C.2.5[55] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated income statement for the period[54] - The company confirms that all directors have complied with the standards of conduct for securities trading during the reporting period[50] - As of March 31, 2021, there are no reported interests or conflicts of interest among directors, supervisors, and management that could compete with the company's business[52] Shareholder Information - As of March 31, 2021, Mr. Wu Le Bin holds 3,500,878 shares, representing 4.35% of the company's domestic shares and 2.42% of the total registered capital[43] - Major shareholder Beijing Puxi Asset Management Co., Ltd. owns 31,308,576 domestic shares, accounting for 38.93% of the domestic shares and 21.64% of the total registered capital[45] - Mr. Wang Tao directly holds 24,506,143 shares, which is 30.47% of the domestic shares and 16.93% of the total registered capital[45] Internal Controls and Risk Management - The company has decided not to establish an internal audit department due to its scale and operational structure, but has implemented measures for risk management and internal control[59] - The company is currently reviewing insurance quotes to purchase liability insurance for its directors within 2021[58] Dividend Policy - The company does not recommend the distribution of an interim dividend for the three months ended March 31, 2021[32] Product Registration - The company completed the continuation registration of 67 products, including the lipoprotein (a) assay kit (immunoturbidimetric method), and obtained a Class I product filing for cleaning agents[40] Taxation - The company has maintained a 15% preferential tax rate due to its classification as a high-tech enterprise, compared to the standard 25% corporate income tax rate in China[4]
中生北控生物科技(08247) - 2021 Q1 - 季度财报